Stock listing
NASDAQ:ALLR Allarity Therapeutics, Inc. Stock
Home listing (NASDAQ) of Allarity Therapeutics, Inc.
Follow Allarity Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ALLR
$0.785 USD -0.087 (-10.0%)
Close on Nov 20, 2026
- Day range
- $0.780 – $0.891 USDNov 20, 2026
- Volume
- 305,151 sharesNov 20, 2026
- Market cap
- $12.56M USDAt the close on Nov 20, 2026 · price × 16.00M shares outstanding
- 52-week range
- $0.769 – $1.840 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $133,763 USDMedian day 108,498 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ALLR · Home | $0.785 USD | -0.087 (-10.0%) | 305,151 | $0.840 | $0.891 | $0.780 | $0.872 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ALLR · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.785 | -0.087 | -10.0% | $0.840 | $0.891 | $0.780 | 305,151 | |
| $0.872 | +0.031 | +3.7% | $0.845 | $0.899 | $0.840 | 290,796 | |
| $0.841 | -0.034 | -3.9% | $0.879 | $0.889 | $0.818 | 213,175 | |
| $0.875 | -0.079 | -8.2% | $0.950 | $0.965 | $0.865 | 196,914 | |
| $0.954 | +0.040 | +4.4% | $0.930 | $0.999 | $0.880 | 279,178 | |
| $0.914 | -0.022 | -2.3% | $0.931 | $0.970 | $0.880 | 77,798 | |
| $0.935 | +0.025 | +2.8% | $0.910 | $0.956 | $0.890 | 97,139 | |
| $0.910 | -0.033 | -3.5% | $0.940 | $0.985 | $0.907 | 82,871 | |
| $0.943 | -0.022 | -2.3% | $0.970 | $1.000 | $0.930 | 73,898 | |
| $0.965 | -0.011 | -1.1% | $0.960 | $0.990 | $0.960 | 64,280 | |
| $0.976 | -0.104 | -9.6% | $1.090 | $1.100 | $0.950 | 155,324 | |
| $1.080 | -0.050 | -4.4% | $1.150 | $1.180 | $1.070 | 135,808 | |
| $1.130 | +0.152 | +15.6% | $0.980 | $1.130 | $0.980 | 320,357 | |
| $0.978 | +0.107 | +12.3% | $0.874 | $1.030 | $0.874 | 166,742 | |
| $0.870 | -0.020 | -2.2% | $0.890 | $0.905 | $0.850 | 176,267 | |
| $0.890 | -0.060 | -6.3% | $0.938 | $0.938 | $0.854 | 150,036 | |
| $0.950 | +0.030 | +3.3% | $0.930 | $0.959 | $0.910 | 69,802 | |
| $0.920 | +0.005 | +0.5% | $0.930 | $0.960 | $0.900 | 136,055 | |
| $0.915 | +0.050 | +5.7% | $0.873 | $0.958 | $0.870 | 174,219 | |
| $0.865 | +0.019 | +2.2% | $0.842 | $0.896 | $0.840 | 70,570 | |
| $0.847 | -0.033 | -3.8% | $0.880 | $0.880 | $0.832 | 90,822 | |
| $0.880 | +0.004 | +0.4% | $0.873 | $0.902 | $0.840 | 88,643 | |
| $0.876 | +0.003 | +0.3% | $0.890 | $0.908 | $0.870 | 108,498 | |
| $0.873 | -0.022 | -2.5% | $0.898 | $0.915 | $0.821 | 86,465 | |
| $0.895 | +0.062 | +7.5% | $0.871 | $0.920 | $0.821 | 232,063 | |
| $0.833 | -0.041 | -4.6% | $0.897 | $0.900 | $0.800 | 323,178 | |
| $0.873 | +0.003 | +0.4% | $0.882 | $0.890 | $0.860 | 64,077 | |
| $0.870 | +0.010 | +1.2% | $0.880 | $0.910 | $0.830 | 111,400 | |
| $0.860 | -0.130 | -13.1% | $0.970 | $0.990 | $0.832 | 415,200 | |
| $0.990 | +0.008 | +0.8% | $0.995 | $1.040 | $0.990 | 97,000 | |
| $0.982 | -0.002 | -0.2% | $0.995 | $1.000 | $0.950 | 63,500 | |
| $0.984 | -0.001 | -0.1% | $1.020 | $1.040 | $0.981 | 81,000 | |
| $0.985 | -0.015 | -1.5% | $0.983 | $1.000 | $0.980 | 45,300 | |
| $1.000 | -0.040 | -3.8% | $1.040 | $1.050 | $0.990 | 39,100 | |
| $1.040 | 0.000 | 0.0% | $1.055 | $1.080 | $1.030 | 28,900 | |
| $1.040 | -0.010 | -1.0% | $1.060 | $1.079 | $1.010 | 74,100 | |
| $1.050 | +0.085 | +8.8% | $0.989 | $1.078 | $0.968 | 119,100 | |
| $0.965 | -0.003 | -0.3% | $0.972 | $1.000 | $0.940 | 167,600 | |
| $0.968 | -0.062 | -6.0% | $1.030 | $1.083 | $0.901 | 270,900 | |
| $1.030 | -0.060 | -5.5% | $1.090 | $1.100 | $1.030 | 43,700 | |
| $1.090 | +0.050 | +4.8% | $1.060 | $1.090 | $1.030 | 75,000 | |
| $1.040 | -0.070 | -6.3% | $1.150 | $1.150 | $1.010 | 167,500 | |
| $1.110 | -0.060 | -5.1% | $1.170 | $1.230 | $1.100 | 182,900 | |
| $1.170 | -0.040 | -3.3% | $1.200 | $1.200 | $1.130 | 114,900 | |
| $1.210 | +0.050 | +4.3% | $1.150 | $1.220 | $1.110 | 185,600 | |
| $1.160 | +0.005 | +0.4% | $1.130 | $1.267 | $1.130 | 160,400 | |
| $1.155 | +0.045 | +4.1% | $1.130 | $1.200 | $1.110 | 53,500 | |
| $1.110 | -0.060 | -5.1% | $1.160 | $1.195 | $1.090 | 154,500 | |
| $1.170 | -0.050 | -4.1% | $1.200 | $1.230 | $1.170 | 112,600 | |
| $1.220 | -0.030 | -2.4% | $1.320 | $1.340 | $1.210 | 205,200 | |
| $1.250 | -0.012 | -1.0% | $1.290 | $1.350 | $1.220 | 79,300 | |
| $1.262 | +0.012 | +1.0% | $1.280 | $1.290 | $1.250 | 65,300 | |
| $1.250 | -0.170 | -12.0% | $1.360 | $1.374 | $1.250 | 236,600 | |
| $1.420 | -0.010 | -0.7% | $1.440 | $1.450 | $1.400 | 54,500 | |
| $1.430 | +0.020 | +1.4% | $1.430 | $1.480 | $1.390 | 43,800 | |
| $1.410 | -0.010 | -0.7% | $1.450 | $1.490 | $1.370 | 124,000 | |
| $1.420 | +0.010 | +0.7% | $1.410 | $1.430 | $1.370 | 54,000 | |
| $1.410 | 0.000 | 0.0% | $1.410 | $1.440 | $1.320 | 106,300 | |
| $1.410 | +0.030 | +2.2% | $1.380 | $1.460 | $1.350 | 139,600 | |
| $1.380 | +0.040 | +3.0% | $1.350 | $1.430 | $1.340 | 49,800 | |
| $1.340 | +0.010 | +0.8% | $1.360 | $1.410 | $1.340 | 44,600 | |
| $1.330 | -0.060 | -4.3% | $1.380 | $1.410 | $1.330 | 57,919 | |
| $1.390 | -0.030 | -2.1% | $1.420 | $1.420 | $1.370 | 32,852 | |
| $1.420 | -0.010 | -0.7% | $1.410 | $1.492 | $1.380 | 111,700 | |
| $1.430 | 0.000 | 0.0% | $1.410 | $1.490 | $1.390 | 78,600 |
Splits
4 splits since 2023 · NASDAQ:ALLR · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-30 | Consolidation | |
| 1-for-20 | Consolidation | |
| 1-for-40 | Consolidation | |
| 1-for-35 | Consolidation |
- Ticker
- NASDAQ:ALLR
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 18, 2026
Allarity Therapeutics Granted U.S. Patent for Stenoparib’s Clinical Dosing Regimen, with Protection Into 2045
Latest deck · May 8, 2026
Investor Presentation (May 2026)
Investor deck · 22 slides
Latest news
Allarity Therapeutics Granted U.S. Patent for Stenoparib’s Clinical Dosing Regimen, with Protection Into 2045
Nov 18, 2026
Closed $0.872 (+3.7%) on Nov 18, 2026
Allarity Therapeutics Expands Phase 2 Stenoparib Trial to Three Ovarian Cancer Patient Cohorts
Nov 16, 2026
Closed $0.875 (-8.2%) on Nov 16, 2026
Allarity Therapeutics Reports Third Quarter 2026 Results and Provides Full Year 2026 Financial Guidance
Nov 13, 2026
Closed $0.954 (+4.4%) on Nov 13, 2026
Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue
Oct 30, 2026
Closed $0.87 (-2.2%) on Oct 30, 2026
Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development
Sep 30, 2026
Closed $1.05 (+8.8%) on Sep 30, 2026
Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
Sep 28, 2026
Closed $0.968 (-6.0%) on Sep 28, 2026
Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
Sep 15, 2026
Closed $1.11 (-5.1%) on Sep 15, 2026
Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement
Sep 11, 2026
Closed $1.22 (-2.4%) on Sep 11, 2026
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign
Aug 14, 2026
Closed $1.37 (+0.7%) on Aug 14, 2026
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration
Jul 7, 2026
Closed $1.13 (-5.8%) on Jul 7, 2026
Allarity Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 22 in the last 12 months · 109 in all · newest Nov 18, 2026 · oldest 2022
- Decks
- 13 decks · latest May 8, 2026
Where Allarity Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ALLR · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ALLR | BOATS | United States | USD |
Valuation
EV/sales 61.4× against a median of 7.5×: the highest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $21.48M USD
- P/E
- Loss
- EV/sales
- 61.4×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.40
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Allarity Therapeutics, Inc. · NASDAQ:ALLR | US$12.56M | US$21.48M | n/a | 61.4× | n/a | n/a | n/a | n/a | 1.40 |
| Devonian Health Group, Inc. · TSXV:GSD | US$13.09M | US$12.59M | n/a | 6.0× | n/a | 2.7× | −204.1% | 0.0× | 0.12 |
| Bolt Biotherapeutics, Inc. · NASDAQ:BOLT | US$12.80M | US$18.89M | n/a | 7.5× | n/a | 1.5× | n/a | 2.4× | 0.52 |
| Avai Bio, Inc. · OTC:AVAI | US$12.79M | US$12.67M | n/a | n/a | n/a | n/a | n/a | n/a | 0.28 |
| Neuphoria Therapeutics Inc. · NASDAQ:NEUP | US$12.72M | −US$6.03M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 0.61 |
| Seres Therapeutics, Inc. · NASDAQ:MCRB | US$12.64M | US$30.89M | n/a | 14.5× | n/a | 0.6× | n/a | 1.7× | 1.21 |
| Passage Bio, Inc. · NASDAQ:PASG | US$12.61M | −US$7.55M | n/a | n/a | n/a | 252× | n/a | 0.0× | 1.94 |
| Lobe Sciences Ltd · CSE:LOBE | US$12.52M | US$8.89M | n/a | n/a | n/a | 9.5× | n/a | 0.0× | 0.31 |
| Biophytis SA · EURONEXT:ALBPS | US$12.47M | US$19.44M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| MIRA Pharmaceuticals, Inc. · NASDAQ:MIRA | US$12.23M | US$5.26M | n/a | n/a | n/a | 1.8× | n/a | 0.0× | 1.48 |
| Genflow Biosciences PLC · LSE:GENF | US$12.06M | US$11.23M | n/a | n/a | n/a | 48.5× | n/a | 0.0× | n/a |
| Median of the others | US$12.63M | US$11.91M | 7.5× | 2.2× | −204.1% | 0.0× | 0.56 |
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.
- Price target
- 11.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.80 · 1 analyst
- Revenue, year to Dec 2026
- 25K · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Thomas Jensen | Chief Executive Officer, Board Member |
| Jeff Ervin | Chief Financial Officer |
| Jeremy R. Graff | President and Chief Development Officer |
| Steen Knudsen | Chief Scientific Officer, Founder |
Board
| Director | Role |
|---|---|
| Jerry McLaughlin | Chairman, Independent Board Member |
| Jesper Høiland | Independent Board Member |
| Laura Benjamin | Independent Board Member |
| Thomas Jensen | Chief Executive Officer, Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 · Before open | +4.4% |
| Q2 2026 | Aug 14, 2026 · Before open | +0.7% |
| Q1 2026 | May 15, 2026 · After close | +5.9% |
| Q3 2025 | Nov 14, 2025 · Before open | −0.8% |
| Q2 2025 | Aug 15, 2025 · After close | −5.0% |
| Q1 2025 | May 9, 2025 | −4.7% |
| Q4 2024 | Mar 31, 2025 | −12.5% |
| Q3 2024 | Nov 14, 2024 · Before open | −2.8% |
| Q2 2024 | Aug 5, 2024 · After close | −5.8% |
| Q1 2024 | May 14, 2024 · After close | −13.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 8, 2024 · Before open | −0.7% |
| Q3 2023 | Nov 14, 2023 · Before open | 0.0% |
| Q2 2023 | Aug 14, 2023 · After close | −7.6% |
| Q1 2023 | May 11, 2023 · After close | −10.0% |
| Q4 2022 | Mar 13, 2023 · After close | −5.5% |
| Q3 2022 | Nov 14, 2022 · After close | −9.0% |
| Q2 2022 | Aug 22, 2022 · After close | −23.7% |
| Q1 2022 | May 27, 2022 · After close | −1.4% |
| Quarter to Sep 30, 2021 | Dec 21, 2021 | |
| Quarter to Jun 30, 2021 | Sep 30, 2021 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (May 2026) | Investor deck | 22 slides | May 8, 2026 |
| Investor Presentation (May 2025) | Investor deck | 24 slides | May 2025 |
| Corporate Update (February 2024) | Corporate update | 16 slides | February 2024 |
| Investor Presentation (December 2023) | Investor deck | 45 slides | Dec 6, 2023 |
| Investor Presentation (November 2023) | Investor deck | 42 slides | Nov 13, 2023 |
| Investor Presentation (March 2023) | Investor deck | 37 slides | Mar 9, 2023 |
| Ladenburg Healthcare Conference September 2022 | Conference | 23 slides | Sep 26, 2022 |
| Investor Presentation (August 2022) | Investor deck | 39 slides | Aug 29, 2022 |
| Investor Presentation (May 2022) | Investor deck | 38 slides | May 27, 2022 |
| Investor Presentation (January 2022) | Investor deck | 40 slides | Jan 18, 2022 |
All 13 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (October 2021) | Merger or acquisition | 37 slides | Oct 8, 2021 |
| Oncology Venture — Shareholder Meeting (March 2020) | Shareholder meeting | 8 slides | Mar 31, 2020 |
| Oncology Venture — Fact Sheet (April 2019) | Fact sheet | 2 slides | April 2019 |
Financings
| Raise | Date |
|---|---|
| At-the-market programme of shares under At-the-Market (ATM) offering program Closed: at-the-market programme | May 9, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 320.0K | 0 | 0 | 0 | 0 | 0 | 120.0K | 1.46M | 1.46M | 143.3K |
| Cost of revenue | 9.00K | 37.0K | 120.0K | 106.0K | 86.0K | 5.08M | 2.22M | |||
| Gross profit | 320.0K | -9.00K | -37.0K | -2.27M | -106.0K | -86.0K | 120.0K | -3.62M | -761.5K | 143.3K |
| Research and development | 6.60M | 6.10M | 7.10M | 6.93M | 14.2M | 4.22M | 6.37M | |||
| Selling, general and administrative | 6.32M | 11.4M | 10.0M | 9.96M | 12.4M | 4.10M | 3.87M | |||
| Operating income | -12.6M | -27.2M | -17.1M | -34.5M | -26.6M | -8.32M | -17.6M | -4.98M | -3.84M | -4.49M |
| Depreciation and amortization | 13.0K | 9.00K | 37.0K | 60.0K | 106.0K | 46.0K | 51.0K | 32.5K | 8.70K | 278.2K |
| EBITDA | -12.6M | -27.2M | -17.1M | -34.4M | -26.4M | -8.27M | -17.6M | -4.95M | -3.83M | -4.21M |
| Interest expense | 185.0K | 653.0K | 498.0K | 223.0K | 99.0K | 93.0K | 3.31M | 233.2K | 2.42K | 43.7K |
| Income before tax | -11.2M | -24.9M | -11.8M | -17.6M | -26.5M | -6.42M | -19.0M | -3.46M | -4.99M | -4.45M |
| Income tax | 0 | -381.0K | 83.0K | -1.52M | 133.0K | 198.0K | -4.58M | -1.07M | -95.1K | -766.9K |
| Net income | -11.2M | -24.5M | -11.9M | -16.1M | -26.6M | -6.62M | -14.3M | -2.29M | -4.90M | -3.68M |
| Earnings per share, basic | -0.78 | -15.65 | -6,031.31 | -3,093.42 | -4.19 | -2.03 | ||||
| Earnings per share, diluted | -10.26 | -3,093.42 | -4.19 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 14.7M | 19.5M | 166.0K | 2.03M | 19.6M | 298.0K | 1.52M | 237.4K | 536.0K | 2.07M |
| Short-term investments | 72.0K | 0 | 350.0K | |||||||
| Receivables | 895.0K | 2.23M | 946.0K | 871.0K | 1.34M | 1.12M | 1.66M | 10.8M | 407.7K | 2.31K |
| Inventory | -1.34M | -2.00K | 168.9K | 34.7K | ||||||
| Current assets | 17.9M | 22.3M | 1.97M | 4.97M | 21.4M | 1.72M | 3.34M | 2.21M | 1.31M | 4.37M |
| Property, plant and equipment | 330.0K | 309.0K | 20.0K | 21.0K | 8.00K | 21.0K | 2.92M | 363.0K | 135.0K | |
| Goodwill | 1.91M | |||||||||
| Total assets | 18.3M | 22.6M | 11.9M | 14.5M | 49.6M | 33.4M | 31.6M | 38.6M | 2.09M | 6.54M |
| Accounts payable | 4.28M | 4.18M | 8.42M | 6.25M | 698.0K | 2.12M | 2.18M | 1.94M | 472.4K | 1.27M |
| Current liabilities | 8.43M | 10.8M | 14.2M | 11.2M | 20.7M | 5.53M | 4.72M | 5.43M | 1.70M | 1.34M |
| Long-term debt | 1.08M | 979.0K | 880.0K | |||||||
| Total debt | 1.40M | 1.35M | 2.69M | 2.64M | 1.09M | 1.79M | 963.0K | 2.90M | ||
| Total liabilities | 8.43M | 10.8M | 14.6M | 12.7M | 30.8M | 8.96M | 10.7M | 10.7M | 1.70M | 1.34M |
| Shareholders' equity | 9.83M | 11.8M | -2.75M | -113.0K | 18.2M | 24.4M | 20.9M | 27.9M | 394.0K | 5.20M |
| Shares outstanding | 16.1M | 7.30M | 9.81K | 11.4K | 8.10M | 4.25M | 4 | 4 | 4 | 4 |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -14.8M | -17.4M | -12.7M | -16.8M | -14.9M | -7.25M | -10.1M | -4.24M | -1.34M | -3.98M |
| Capital spending | -8.00K | -298.0K | 0 | -18.0K | -18.0K | -3.00K | -8.00K | -5.68K | -37.0K | -77.8K |
| Free cash flow | -14.8M | -17.6M | -12.7M | -16.8M | -15.1M | -7.25M | -10.1M | -4.24M | -1.34M | -4.06M |
| Cash from investing | -8.00K | -298.0K | 0 | 791.0K | 1.00M | -3.00K | 229.0K | 1.51M | -128.0K | -178.7K |
| Cash from financing | 10.6M | 36.8M | 11.0M | -1.31M | 33.8M | 6.03M | 11.2M | 2.42M | 1.16M | 4.31M |
| Dividends paid | -11.0M | -1.51M | ||||||||
| Share buybacks | -3.19M | 0 | -6.65M | -1.51M | 0 | |||||
| Change in cash | -4.18M | 19.1M | -1.75M | -17.3M | 19.9M | -1.22M | 1.29M | -298.6K | -1.54M | 2.07M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 19, 2026 | Current report | SEC |
| 8-K · Current report | Nov 17, 2026 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 2, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Oct 30, 2026 | Offer document | SEC |
| 8-K · Current report | Oct 30, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 1, 2026 | Current report | SEC |
| 8-K · Current report | Sep 29, 2026 | Current report | SEC |
| 8-K · Current report | Sep 16, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Sep 14, 2026 | Current report | SEC |
| 8-K · Current report | Aug 14, 2026 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 1, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 22, 2026 | Current report | SEC |
| 8-K · Current report | Jun 2, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | May 15, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 11, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 11, 2026 | Insider trade | SEC |
| 8-K · Current report | May 8, 2026 | Current report | SEC |
| 4 · Change in ownership | May 7, 2026 | Insider trade | SEC |
| 8-K · Current report | May 6, 2026 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 30, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2026 | Meeting notice | SEC |
| 4/A · Change in ownership, amended | Apr 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 30, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 28, 2026 | Current report | SEC |
| 424B3 · Prospectus | Apr 27, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 27, 2026 | Other filings | SEC |
| S-3/A · Registration statement, amended | Apr 24, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 22, 2026 | Other filings | SEC |
| 8-K · Current report | Apr 22, 2026 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Apr 10, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 1, 2026 | Results | SEC |
| 10-K · Annual report | Mar 30, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 9, 2026 | Current report | SEC |
| 8-K · Current report | Mar 6, 2026 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Feb 19, 2026 | Other filings | SEC |
| 8-K · Current report | Feb 19, 2026 | Current report | SEC |
| S-3 · Registration statement | Feb 12, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 4, 2026 | Current report | SEC |
| 424B5 · Prospectus | Jan 29, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 29, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jan 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Dec 23, 2025 | Financing | SEC |
| 8-K · Current report | Dec 8, 2025 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Dec 8, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 4, 2025 | Other filings | SEC |
| S-3 · Registration statement | Dec 3, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Oct 1, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Sep 30, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Sep 30, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 29, 2025 | Other filings | SEC |
| S-3 · Registration statement | Sep 25, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 24, 2025 | Current report | SEC |
| 8-K · Current report | Sep 22, 2025 | Material contract | SEC |
| 8-K · Current report | Sep 19, 2025 | Current report | SEC |
| 8-K · Current report | Aug 27, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 15, 2025 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Aug 14, 2025 | Explanation request | SEC |
| 8-K · Current report | Jul 16, 2025 | Current report | SEC |
| 3 · Initial statement of ownership | Jul 14, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 7, 2025 | Management or board change | SEC |
| 8-K · Current report | Jul 1, 2025 | Current report | SEC |
| 8-K · Current report | Jun 30, 2025 | Current report | SEC |
| RW · Request to withdraw a registration | Jun 24, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 20, 2025 | Other filings | SEC |
| 8-K · Current report | Jun 17, 2025 | Meeting outcome | SEC |
| DRS · Draft registration statement | Jun 16, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 11, 2025 | Management or board change | SEC |
| 8-K · Current report | Jun 5, 2025 | Current report | SEC |
| 8-K · Current report | Jun 3, 2025 | Current report | SEC |
| 8-K · Current report | May 13, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 9, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 30, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 30, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 30, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 28, 2025 | Current report | SEC |
| 8-K · Current report | Apr 16, 2025 | Management or board change | SEC |
| 10-K · Annual report | Mar 31, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| 8-K · Current report | Mar 25, 2025 | Current report | SEC |
| 8-K · Current report | Mar 18, 2025 | Current report | SEC |
| 8-K · Current report | Mar 14, 2025 | Current report | SEC |
| 8-K · Current report | Mar 7, 2025 | Current report | SEC |
| 8-K · Current report | Mar 4, 2025 | Current report | SEC |
| 8-K · Current report | Feb 27, 2025 | Current report | SEC |
| 8-K · Current report | Feb 25, 2025 | Current report | SEC |
| 8-K · Current report | Feb 7, 2025 | Current report | SEC |
| 8-K · Current report | Jan 30, 2025 | Current report | SEC |
| 4/A · Change in ownership, amended | Jan 24, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jan 24, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 19, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 23, 2024 | Current report | SEC |
| 8-K · Current report | Oct 11, 2024 | Current report | SEC |
| 8-K · Current report | Oct 4, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Oct 1, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 1, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 18, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 17, 2024 | Current report | SEC |
| 8-K · Current report | Sep 13, 2024 | Material contract | SEC |
| 8-K/A · Current report, amended | Sep 10, 2024 | Management or board change | SEC |
| 424B5 · Prospectus | Sep 9, 2024 | Offer document | SEC |
| 8-K · Current report | Sep 9, 2024 | Management or board change | SEC |
| S-3 · Registration statement | Aug 30, 2024 | Offer document | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 29, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Aug 29, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Aug 21, 2024 | Material contract | SEC |
| DEFR14A | Aug 19, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 5, 2024 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Jul 26, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jul 23, 2024 | Current report | SEC |
| 8-K · Current report | Jul 22, 2024 | Current report | SEC |
| ARS · Annual report to shareholders | Jul 1, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Jul 1, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jun 28, 2024 | Current report | SEC |
| 8-K · Current report | Jun 26, 2024 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Jun 21, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jun 21, 2024 | Current report | SEC |
| 8-K · Current report | Jun 6, 2024 | Management or board change | SEC |
| 8-K/A · Current report, amended | May 24, 2024 | Results | SEC |
| 8-K · Current report | May 21, 2024 | Material contract | SEC |
| 424B5 · Prospectus | May 17, 2024 | Offer document | SEC |
| 8-K · Current report | May 15, 2024 | Results | SEC |
| 424B5 · Prospectus | May 14, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 424B5 · Prospectus | May 9, 2024 | Offer document | SEC |
| 8-K · Current report | May 9, 2024 | Current report | SEC |
| RW · Request to withdraw a registration | May 8, 2024 | Other filings | SEC |
| 8-K · Current report | May 6, 2024 | Current report | SEC |
| 424B5 · Prospectus | May 6, 2024 | Offer document | SEC |
| 8-K · Current report | May 3, 2024 | Current report | SEC |
| 424B5 · Prospectus | May 2, 2024 | Offer document | SEC |
| 424B5 · Prospectus | May 2, 2024 | Offer document | SEC |
| 424B5 · Prospectus | May 2, 2024 | Offer document | SEC |
| 8-K · Current report | Apr 30, 2024 | Current report | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2024 | Annual report | SEC |
| 8-K · Current report | Apr 18, 2024 | Current report | SEC |
| S-1/A · Registration statement, amended | Apr 17, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Apr 15, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Apr 12, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Apr 11, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Apr 9, 2024 | Offer document | SEC |
| S-1/A · Registration statement, amended | Apr 5, 2024 | Offer document | SEC |
| 8-K · Current report | Apr 5, 2024 | Current report | SEC |
| 8-K · Current report | Apr 4, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Apr 1, 2024 | Current report | SEC |
| 8-K · Current report | Mar 26, 2024 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 25, 2024 | Offer document | SEC |
| 8-K · Current report | Mar 19, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Mar 19, 2024 | Offer document | SEC |
| 8-K · Current report | Mar 15, 2024 | Material contract | SEC |
| 8-K · Current report | Mar 8, 2024 | Results | SEC |
| 10-K · Annual report | Mar 8, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Mar 7, 2024 | Meeting notice | SEC |
| 8-K · Current report | Mar 4, 2024 | Management or board change | SEC |
| 8-K · Current report | Mar 1, 2024 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Feb 27, 2024 | Other filings | SEC |
| PRER14A | Feb 23, 2024 | Other filings | SEC |
| 8-K · Current report | Feb 14, 2024 | Material contract | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 12, 2024 | Big-stake notice | SEC |
| D | Feb 2, 2024 | Other filings | SEC |
| 8-K · Current report | Feb 1, 2024 | Management or board change | SEC |
| PRE 14A · Preliminary proxy statement | Jan 26, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jan 25, 2024 | Material contract | SEC |
| 8-K · Current report | Jan 19, 2024 | Material contract | SEC |
| S-1/A · Registration statement, amended | Dec 15, 2023 | Offer document | SEC |
| 8-K · Current report | Dec 11, 2023 | Management or board change | SEC |
| 8-K · Current report | Dec 6, 2023 | Current report | SEC |
| S-1/A · Registration statement, amended | Dec 6, 2023 | Offer document | SEC |
| 8-K · Current report | Dec 5, 2023 | Current report | SEC |
| S-1/A · Registration statement, amended | Dec 4, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Nov 30, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 27, 2023 | Other filings | SEC |
| 8-K · Current report | Nov 17, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2023 | Current report | SEC |
| UPLOAD · Letter from the SEC | Nov 8, 2023 | Other filings | SEC |
| S-3 · Registration statement | Nov 2, 2023 | Offer document | SEC |
| S-1 · Registration statement | Oct 31, 2023 | Offer document | SEC |
| 8-K · Current report | Oct 30, 2023 | Current report | SEC |
| 424B3 · Prospectus | Oct 23, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Oct 20, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 17, 2023 | Other filings | SEC |
| S-3/A · Registration statement, amended | Oct 17, 2023 | Offer document | SEC |
This page holds 200 of 406 filings. Open Filings
Cap table
Built by 6ix from Allarity Therapeutics, Inc.’s releases · as of Nov 12, 2026
- Common shares
- 15,997,108
- Fully diluted
- 15,997,108
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 15,997,108 | Nov 12, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 12, 2026 | 15,997,108 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Gerald W McLaughlin Other companies: Aytu BioPharma, Inc. (Director · Mar 19, 2021 – Apr 8, 2021 · Past); Neos Therapeutics Inc (Chief Executive Officer, Director · Mar 2, 2020 – Mar 19, 2021 · Past) | Director · Since at least Oct 1, 2022 |
| David Roth Other companies: Syros Pharmaceuticals, Inc. (Chief Medical Officer · Jun 29, 2016 – Nov 18, 2024 · Past) | Director · Jul 7, 2022 – Jul 7, 2022 · Past |
| Jeffrey S Ervin Other companies: Cingulate Inc. (Director · Since at least Feb 12, 2024) | CFO · Since at least Jul 1, 2025 |
| Jeremy R. Graff Other companies: IN8bio, Inc. (Director · Since at least May 1, 2023) | See Remarks · Since at least Sep 30, 2024 |
| Steve Carchedi Other companies: Sunesis Pharmaceuticals Inc (Director · Jun 20, 2013 – Jun 30, 2020 · Past) | Chief Executive Officer, Director · Dec 20, 2021 – Dec 20, 2021 · Past |
| Thomas Jensen Other companies: Valion Bio, Inc. (Director · Since at least Aug 27, 2026) | CEO · Since at least Dec 20, 2021 |
| Alexander Epshinsky | CFO · Sep 12, 2024 – Jan 22, 2025 · Past |
| James G Cullem | SVP, Chief Business Officer · Dec 20, 2021 – Dec 20, 2021 · Past |
| Jeff Ervin | Chief Financial Officer · Since at least Mar 31, 2026 |
| Jens Erik Knudsen | Former Chief Financial Officer · Dec 20, 2021 – Jun 27, 2022 · Past |
All 17 people
| Person | Seat |
|---|---|
| Jerry McLaughlin | Chairman, Independent Board Member · Since at least Jun 11, 2025 |
| Jesper Hoeiland | Director · Since at least Jun 10, 2025 |
| Jesper Høiland | Independent Board Member · Since at least Mar 31, 2026 |
| Joan Yvonne Brown | Chief Financial Officer · Jun 29, 2022 – Jun 29, 2022 · Past |
| Laura Benjamin | Independent Board Member · Since at least Aug 1, 2023 |
| Marie Foegh | Chief Medical Officer · Dec 20, 2021 – Dec 20, 2021 · Past |
| Steen Knudsen | Chief Scientific Officer, Founder · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Allarity Therapeutics, Inc.